Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249483 · ClinicalTrials.gov registry record · Phase 2
Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals
A Phase 2 study of Cocaine-Related Disorders, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00249483: Completed Phase 2 study of Cocaine-Related Disorders, sponsored by New York State Psychiatric Institute.
NCT00249483 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 150 participants, above the 55-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (173% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00249483, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Preliminary research has shown that venlafaxine, a medication currently used for treating depression, may also discourage cocaine use in depressed individuals. This study will evaluate the effectiveness of venlafaxine in reducing cocaine use and alleviating depression in individuals addicted to cocaine.
Primary Outcome
Proportion of patients achieving 3 weeks of cocaine abstinence based on self report and urine toxicology
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Venlafaxine
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1999-10 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
What the finished NCT00249483 record still lists
NCT00249483 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 55-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (173% higher).
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00249483 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00249483 about?
NCT00249483 is a clinical study titled "Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals". Preliminary research has shown that venlafaxine, a medication currently used for treating depression, may also discourage cocaine use in depressed individuals. This study will evaluate the effectiveness of venlafaxine in reducing cocaine use and alleviating depression in individuals addicted to coca...
What is the current status of trial NCT00249483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 1999-10. Estimated completion is 2005-02.
What conditions does trial NCT00249483 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
What interventions are being tested in trial NCT00249483?
The interventions under investigation include: Placebo (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00249483?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00249483 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00249483's enrollment target sits among peer trials
150 2nd of 15 the highest of 15 other Cocaine-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia